Tempus AITEM stock surged to a record high Monday after the Food and Drug Administration cleared its new device to help ...

ABBV eyes a 2025 rebound as Skyrizi and Rinvoq drive growth beyond Humira, with oncology and neuroscience adding momentum.

Absci, which engineers biologic drugs based on its own generative AI platform, has advanced its lead candidate into the clinic by dosing the first healthy volunteers. The trial is designed to assess ...

Genentech continues to study the drug in lung-scarring idiopathic pulmonary fibrosis as well as a new study in ulcerative colitis. Eyes have it: Peninsula biotech focuses on glaucoma, more in big test ...

With a fresh endorsement from the FDA, Johnson & Johnson has rounded out Tremfya’s presence in inflammatory bowel disease ...

Scientists headed by a team at the University of British Columbia (UBC) have developed a new approach to drug design that can deliver therapeutics directly to a specific part of the gastrointestinal ...

A new drug delivery method could improve treatments for inflammatory bowel disease (IBD) like ulcerative colitis and Crohn’s disease. Currently available oral drugs for IBD must transit the entire ...

A Spanish trial finds similar sustained IBD clinical remission rates 1-year post-withdrawal vs maintenance of anti-TNF ...

Meanwhile, a systematic review and meta-analysis in Lancet Gastroenterology & Hepatology examined differences in risks for ...